Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.57 |
| ▸ | OGA | O60502 | 1/20 | 0.53 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.49 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1743852 | 0.90 | HRH3 (0.57) | HRH3OGATLR9TLR8TLR7 | |
| SCHEMBL30109094 | 0.89 | HRH3 (0.69) | HRH3OGA | |
| SCHEMBL1743223 | 0.87 | HRH3 (0.50) | HRH3OGAEGLN1TLR9TLR8 | |
| SCHEMBL1744098 | 0.86 | HRH3 (0.60) | HRH3TLR9TLR8TLR7 | |
| SCHEMBL1742491 | 0.85 | HRH3 (0.51) | HRH3TLR9TLR8TLR7 | |
| SCHEMBL1743019 | 0.84 | HPGD (0.55) | HRH3 | |
| Hydrochloric Acid SCHEMBL4002410 | 0.83 | HPGD (0.54) | HRH3 | |
| SCHEMBL1742384 | 0.83 | ALDH1A1 (0.53) | HRH3 | |
| SCHEMBL27728017 | 0.83 | HRH3 (0.45) | HRH3OGAEGLN1TLR9TLR8 | |
| Hydrochloric Acid SCHEMBL4003401 | 0.82 | ALDH1A1 (0.52) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846677-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8501739-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-08-06 | — | — | US | disclosed |
| CN-103110635-A | Histamine H3 receptor antagonist | NOVO NORDISK AS | 2013-05-22 | — | — | CN | disclosed |
| US-20120232078-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2386554-A1 | Compounds active at the histamine H3 receptor | High Point Pharmaceuticals, LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| EP-2233470-A1 | Histamine H3 receptor antagonists | High Point Pharmaceuticals, LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090312309-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-12-17 | — | — | US | disclosed |
| CN-101218206-A | Histamine H3 receptor antagonists | NOVO NORDISK AS (DK) | 2008-07-09 | — | — | CN | disclosed |
| EP-1902028-A2 | HISTAMINE H3 RECEPTOR ANTAGONISTS | Novo Nordisk A/S (DK) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007003604-A2 | HISTS1MINE H3 RECEPTOR ANTAGONISTS | NOVO NORDISK A/S (DK) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232078-A1 | Novel Medicaments | HRH3, HRH4, HRH1 | HRH3 1/4885OGA 3751/4885EGLN1 1651/4885 |
| US-20090312309-A1 | Novel Medicaments | HRH3, HRH4, HRH1 | HRH3 1/4885OGA 3751/4885EGLN1 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.